Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 17.88B | 18.12B | 16.87B | 14.55B | 13.76B | 14.60B |
Gross Profit | 6.52B | 6.78B | 6.35B | 5.44B | 5.61B | 6.14B |
EBITDA | 2.74B | 3.29B | 2.57B | 2.74B | 3.13B | 2.99B |
Net Income | 1.04B | 1.30B | 943.00M | 1.15B | 1.25B | 1.08B |
Balance Sheet | ||||||
Total Assets | 32.95B | 31.41B | 29.61B | 26.30B | 24.84B | 28.41B |
Cash, Cash Equivalents and Short-Term Investments | 3.58B | 2.78B | 3.27B | 3.07B | 4.40B | 6.46B |
Total Debt | 8.86B | 7.25B | 6.67B | 5.70B | 6.24B | 9.36B |
Total Liabilities | 22.12B | 20.63B | 19.88B | 17.39B | 16.65B | 20.30B |
Stockholders Equity | 10.78B | 10.77B | 9.73B | 8.91B | 8.20B | 8.11B |
Cash Flow | ||||||
Free Cash Flow | 679.00M | 817.00M | 400.00M | 450.00M | 1.71B | 252.00M |
Operating Cash Flow | 2.38B | 2.46B | 1.96B | 1.86B | 2.55B | 1.01B |
Investing Cash Flow | -1.80B | -1.92B | -1.61B | -1.65B | -613.00M | -1.30B |
Financing Cash Flow | 516.00M | -1.10B | -129.00M | -1.73B | -3.60B | 2.62B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | €1.22B | 37.21 | 10.11% | ― | 2.53% | -44.90% | |
64 Neutral | kr18.73B | 79.03 | 2.43% | 4.89% | -0.57% | -81.68% | |
53 Neutral | kr425.83M | ― | -19.17% | ― | -12.50% | -783.92% | |
49 Neutral | AU$2.49B | 4.37 | -64.25% | 2.83% | 36.51% | 13.14% | |
48 Neutral | kr1.22B | ― | -5.61% | ― | 13.66% | -139.90% | |
46 Neutral | kr361.14M | ― | -88.97% | ― | -0.61% | 54.19% | |
34 Underperform | kr67.23M | ― | ― | ― | ― |
Elekta AB reported a 6% increase in net sales for the fourth quarter of 2024/25 at constant exchange rates, driven by strong performance in Europe and APAC, and a 3% increase in reported sales. The company achieved its best fourth-quarter gross margin in five years at 40.3%, supported by price increases, product launches, and a solid performance of its Elekta Evo linear accelerator and Elekta ONE software suite. Despite a non-cash impairment of SEK 1,064 M due to discontinued R&D projects, Elekta maintained a strong book-to-bill ratio and improved cash flow. The company expects continued sales growth and margin improvements, aiming to reach pre-pandemic levels, while its products have received positive feedback from healthcare providers.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta has announced a presentation for its fiscal year 2024/25, scheduled for May 28, where the company’s Acting President and CEO, Jonas Bolander, along with CFO Tobias Hägglöv, will discuss the company’s development. The event, which includes a live webcast and Q&A session, reflects Elekta’s commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.